SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

August 13, 2025 updated by: The First Affiliated Hospital with Nanjing Medical University

An Open Label, Single Arm, Multi-Center Exploratory Study to Evaluate the Efficacy and Safety of SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease.

The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Study Design:

This protocol corresponds to a multicenter, open-label, single arm, exploratory study designed to determine the safety of the combination of selinexor combined with VRd in NDMM patients presenting with EMD. The patients who respond to this combination treatment will undergo allogeneic hematopoietic stem cell transplantation or no ASCT and followed by consolidation and maintenance treatment.

All patients will receive 4 courses of SVRd induction therapy, each cycle of treatment will compromise 4 weeks of Selinexor 60mg QW treatment. Transplantation could be performed after 2 courses of VRd consolidation therapy. If not receive transplantation will give 4 cycles of SVRd consolidation therapy. Maintenance treatment will continued for a maximum of 2 years.

Study design allows 35 patients. Induction treatment will consist of Selinexor 60 mg/day orally on d1,8,15,22, Bortezomib 1.3mg/m2 intravenously on d1,8,15,22, Lenalidomide 25 mg/d ( the dose will be adjusted according to creatinine clearance), orally on days 1 to14, Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23

Study Type

Interventional

Enrollment (Estimated)

35

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Lijuan Chen, Doctor
  • Phone Number: 025-83714511
  • Email: chenljb@126.com

Study Locations

  • China
    • Jiangsu
      • Changzhou, Jiangsu, China, 213000
        • Not yet recruiting
        • Changzhou Second People's Hospital
        • Contact:
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • The First Affiliated Hospital of Nanjing Medical University
        • Contact:
          • Yuanyuan Jin, doctor
      • Nanjing, Jiangsu, China, 210000
        • Not yet recruiting
        • Nanjing First People's Hospital
        • Contact:
      • Nantong, Jiangsu, China, 226001
        • Not yet recruiting
        • Affiliated Hospital of Nantong University
        • Contact:
      • Taizhou, Jiangsu, China, 225300
        • Not yet recruiting
        • Taizhou People's Hospital
        • Contact:
      • Yancheng, Jiangsu, China, 224006
        • Not yet recruiting
        • Yancheng First People's Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Men and women aged with18-75 years old.
  2. Confirmed diagnosis of Multiple Myeloma(MM) (IMWG consensus guidelines)
  3. Newly diagnosed patients presenting with extramedullary disease (EMD) including solely paraskeletal plasmacytoma, plasmacytoma of soft tissue and other special sites detected by physical exam and confirmed by CT/MRI/PET-CT and/or biopsy (≥2cm).
  4. ANC≥1.0*10^9/L, HGB≥75*10^9/L, PLT≥50*10^9/L (≥50% of bone marrow nucleated cells are plasma cells).
  5. Patients whose expecting survival time will be more than 3 months.
  6. Without active infectious disease.
  7. Female patients of child-bearing potential must have a negative serum pregnancy test at screening and all patients agree to use two reliable methods of contraception for six months after their last dose of medication.
  8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
  9. Each patient must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

  1. Patients who have HBV, HCV, and other acquired and congenital immunodeficiency diseases.
  2. Patients who have grade 2 or higher of peripheral neuropathy or neuralgia according to the definition of NCI CTCAE version 4.0.
  3. Plasma cell leukemia.
  4. Serious thrombotic events.
  5. Active, unstable cardiovascular dysfunction: a. symptomatic ischemia; b. Uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia), but patients with first-degree atrioventricular block or asymptomatic left anterior bundle/right fascicular block cannot be excluded. c. New York Heart Association (NYHA) Class III - IV or left ventricular ejection fraction (LVEF) <40%; d. Myocardial infarction Within 3 months before C1D1.
  6. Significant hepatic dysfunction (ALT and AST ≥ 3 times the upper limit of normal (ULN)).
  7. Serum bilirubin≥1.5 × ULN.
  8. creatinine clearance <30 ml/min.
  9. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma.
  10. Previous major operation within 30 days before C1D1.
  11. Patients who have epilepsy, dementia requiring medication, or other mental disorders who are unable to understand or adhere to the study protocol.
  12. According to the study protocol or in the opinion of the investigator,serious physical or mental illness that is likely to interfere with the study procedures/results.
  13. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  14. Current participation in another clinical trial.
  15. Pregnant or lactating women.
  16. Patients with other commodities that the investigators considered not suitable for the enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: study group
SVRd induction treatment
Drug: Selinexor
Selinexor 60 mg/day, orally on d1,8,15,22
Other Names:
  • S
Drug: Bortezomib
Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
Other Names:
  • V
Drug: Lenalidomide
Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
Other Names:
  • R
Drug: Dexamethasone
Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
Other Names:
  • d

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Overall Response Rate (ORR)
Time Frame: End of induction treatment (4 cycles, each cycle is 28 days)
ORR: defined as the proportion of patients who will achieve PR or better, as per IMWG criteria.
End of induction treatment (4 cycles, each cycle is 28 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Complete Response Rate (CR)
Time Frame: End of induction treatment (4 cycles, each cycle is 28 days)
CR: defined as the proportion of patients who will achieve CR, as per IMWG criteria.
End of induction treatment (4 cycles, each cycle is 28 days)
Duration of Response (DOR)
Time Frame: 5 years
DOR: defined as time, in months, from initial response (PR or better) until the date of a disease progression event
5 years
Progression-Free Survival (PFS)
Time Frame: 5 years
PFS: was calculated from the time of informed consent to the date of recurrence or death, whichever occurred first. Patients were censored at the date of the last follow-up visit if they were alive without relapse.
5 years
Overall Survival (OS)
Time Frame: 5 years
OS was calculated from the date of informed consent to the date of death. Patients still alive at the end of follow-up were censored at the last date of follow-up.
5 years
Number of adverse events
Time Frame: During of induction treatment (4 cycles, each cycle is 28 days)
Adverse events are evaluated with CTCAE V5.0.
During of induction treatment (4 cycles, each cycle is 28 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Investigators

  • Study Chair: Lijuan Chen, The First Affiliated Hospital with Nanjing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2022

Primary Completion (Estimated)

August 30, 2025

Study Completion (Estimated)

August 30, 2025

Study Registration Dates

First Submitted

May 29, 2023

First Submitted That Met QC Criteria

June 11, 2023

First Posted (Actual)

June 13, 2023

Study Record Updates

Last Update Posted (Actual)

August 17, 2025

Last Update Submitted That Met QC Criteria

August 13, 2025

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SVRd

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Selinexor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe